Rhythm Pharmaceuticals reported Q1 2026 results on May 5 that pulled in opposite directions on the same printout. Setmelanotide net product revenue, sold under the brand name Imcivree ↗, came in at $60.1 million ($36.9 million in the United States plus $23.2 million ex-US), up from $37.7 million a year earlier. The 59 percent year-over-year jump reflects the launch of acquired hypothalamic obesity in the US following the FDA approval, the EU Marketing Authorization for the same indication that opened ex-US revenue, and Japan's PMDA accepting the company's NDA for review. New US start forms ran above 150 in the quarter on the hypothalamic obesity indication alone. The launch indication is working.
The EMANATE Phase 3 program is not. EMANATE is the four-substudy trial program designed to expand setmelanotide's label into genetically caused MC4R-pathway diseases (heterozygous variants in POMC, PCSK1, LEPR, and other upstream players in the melanocortin signaling cascade). All four substudies missed their primary weight-loss endpoint independently. The miss is not a single negative trial that future work can disentangle; it is a categorical signal that the heterozygous-variant population, which has partial rather than complete loss of MC4R signaling, does not respond to setmelanotide the way the homozygous biallelic-variant population the drug was originally approved for does. The label-expansion runway from rare genetic obesity into a meaningfully larger MC4R-pathway-variant patient set has narrowed materially, possibly closed.
What setmelanotide is. Setmelanotide is a cyclic 8-amino-acid peptide (sequence CRFFNAFC) that selectively activates the MC4R receptor ↗, the central node in the melanocortin pathway that governs energy balance and appetite. It was the first precision-medicine obesity therapy, approved in 2020 for biallelic POMC, PCSK1, and LEPR deficiency, and later extended to Bardet-Biedl syndrome and to acquired hypothalamic obesity (the launch indication driving the Q1 number). The patient populations are vanishingly small by big-pharma standards (the rare genetic forms together cover thousands of patients globally; acquired hypothalamic obesity adds roughly ten times that), which is why the commercial scale of even a successful launch sits in the tens of millions per quarter rather than the hundreds of millions the GLP-1 class delivers.
Why EMANATE was the indication that mattered. The MC4R-pathway variant population EMANATE targeted is large enough to materially change the commercial story. Heterozygous variants in genes upstream of MC4R, particularly POMC and LEPR, occur in a meaningful fraction of severely obese patients (estimates run to several percent of the highest-BMI tail). If the heterozygous variants were sufficient to make those patients setmelanotide-responders, the addressable population would jump by an order of magnitude. The four-substudy miss says they are not.
The cash position holds. Rhythm reported a $56.7 million net loss for the quarter and $340.6 million in cash, which the company said gives it more than 24 months of runway. That is enough time to absorb the EMANATE setback, focus commercial work on the indications that are working, and decide what to advance from the earlier-stage MC4R-pathway pipeline (an oral small-molecule MC4R agonist, a once-weekly setmelanotide formulation, and trials in additional acquired hypothalamic obesity subpopulations). The runway buys time, but it does not generate a new label-expansion path that EMANATE was supposed to open.
The platform read. The melanocortin family is a small but distinctive corner of the platform's target corpus. The MC4R target page hosts the receptor setmelanotide engages, alongside the MC1R, MC2R, and MC3R subtypes that the broader melanocortin literature covers. With EMANATE narrowing the indication-expansion runway for cyclic-octapeptide MC4R agonists in heterozygous-variant populations, the design questions that matter going forward shift toward different patient stratifications (homozygous and acquired indications where the drug works), different molecules (the small-molecule MC4R agonists Rhythm has in earlier stages, where receptor-bias profiles may differ from the cyclic peptide), or different combinations (MC4R plus another satiety axis, the way GLP-1 has gone with GIP and amylin). The platform's MC4R corner is well-positioned for whichever direction the field takes; the EMANATE result narrows which directions are still on the table.
What this is not. A commercial collapse. The launch indication is working at $60 million per quarter and growing, the cash runway holds, and Japan adds an ex-US revenue lane this year. What it is is the closing of a specific label-expansion path that drove a meaningful fraction of the company's three-year commercial story, and a reminder that genetic-pathway-stratified obesity drugs do not necessarily generalize across heterozygous variants in the same pathway. The melanocortin space is not GLP-1, and the MC4R agonist class will continue to operate at small-cohort scale until the next mechanistically distinct expansion lands.